KCNH7
KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Overview
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Exhibits faster activation and deactivation kinetics and slow inactivation at membrane potentials positive to 240 mV, resulting in the weakest inward rectification.
Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.11, genetic association 0.27, clinical 0.76).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 1 · What it is
KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
- 2 · What goes wrong in cancer
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel.
- 3 · How drugs use it
No product in this corpus aims at KCNH7 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:18863 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NS40 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184611 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0))
Biology
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Exhibits faster activation and deactivation kinetics and slow inactivation at membrane potentials positive to 240 mV, resulting in the weakest inward rectification. Location: Cell membrane (UniProt). Locus 2q24.2 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KCNH7" OR ABSTRACT:"KCNH7" OR TITLE:"potassium voltage-gated channel subfamily H member 7" OR ABSTRACT:"potassium voltage-gated channel subfamily H member 7" OR TITLE:"Voltage-gated inwardly rectifying potassium channel KCNH7" OR ABSTRACT:"Voltage-gated inwardly rectifying potassium channel KCNH7" OR TITLE:"Kv11.3" OR ABSTRACT:"Kv11.3" OR TITLE:"HERG3" OR ABSTRACT:"HERG3" OR TITLE:"erg3" OR ABSTRACT:"erg3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNH7, not a curated reading list.